Cerenome Inc. Common Stock (CNSY)
Stock · NASDAQ · Health Care
$1.71as of 10/16/2026
Price chart
Active signals
High Beta63.5%
Resistance level
$3.02
Industry
Medical/Dental Instruments
About CNSY
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 28
- Website
- www.plustherapeutics.com/
Fundamentals
- 1-day range
- $1.66$1.85
- Market cap
- $26.57M
- P/E (trailing)
- —
- P/E (forward)
- -0.74
- EPS (trailing)
- $-4.42
- Dividend yield
- —
- Beta
- 2.39
- Avg. volume
- 112.3K
52-week range
$1.49$4.16
Next earnings: March 12, 2026 · EPS estimate $-0.92confirmed
Forecasts
4 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$43
+2414.6%
Median
$28
+1537.4%
Low
$12
+601.8%
Cerenome Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CNSYCerenome Inc. Common Stock$1.7▼ 9.57%Market cap $26.57MP/E —$1.49$4.16
- CTSOCytosorbents Corporation Common Stock$4.11▲ 34.31%Market cap $25.05MP/E —$2.96$18.8
- BEATHeartbeam Inc. Common Stock$0.436▲ 0.93%Market cap $28.33MP/E —$0.355$4
- PLRZPolyrizon Ltd. Ordinary Shares$10▼ 0.10%Market cap $21.51MP/E —$2.88$18.2
- RVPRetractable Technologies Inc. Common Stock$0.58▼ 1.69%Market cap $20.27MP/E —$0.5844$1.14
- ARAYAccuray Incorporated Common Stock$0.16▼ 5.88%Market cap $33.63MP/E —$0.1615$1.86
- NSPRInspireMD Inc. Common Stock$0.46▼ 4.17%Market cap $33.87MP/E —$0.4604$2.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CNSY Cerenome Inc. Common Stock | $26.57M | — | $1.7 | ▼ 9.57% | $1.49$4.16 |
| CTSO Cytosorbents Corporation Common Stock | $25.05M | — | $4.11 | ▲ 34.31% | $2.96$18.8 |
| BEAT Heartbeam Inc. Common Stock | $28.33M | — | $0.436 | ▲ 0.93% | $0.355$4 |
| PLRZ Polyrizon Ltd. Ordinary Shares | $21.51M | — | $10 | ▼ 0.10% | $2.88$18.2 |
| RVP Retractable Technologies Inc. Common Stock | $20.27M | — | $0.58 | ▼ 1.69% | $0.5844$1.14 |
| ARAY Accuray Incorporated Common Stock | $33.63M | — | $0.16 | ▼ 5.88% | $0.1615$1.86 |
| NSPR InspireMD Inc. Common Stock | $33.87M | — | $0.46 | ▼ 4.17% | $0.4604$2.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile TestsYahoo · 10/8/2026
- Cerenome Launches CNSide® CSF Molecular Profile TestsYahoo · 10/6/2026
- Lake Street Maintains Buy on Cerenome, Lowers Price Target to $31benzinga · 10/1/2026
- Lake Street Maintains Buy on Cerenome, Lowers Price Target to $31Benzinga · 10/1/2026
- Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform TranscriptSeekingAlpha · 9/30/2026
- Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross BillingsYahoo · 9/30/2026
- Cerenome Anticipates $1.55M In Payer Billings In Q3Benzinga · 9/30/2026
- Cerenome to Hold CNSide® Business Update Call on September 30, 2026Yahoo · 9/25/2026
- Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered LivesYahoo · 9/22/2026
Insider Activity
Insider Actions →Acquired
24.0K
Disposed
0
- HEDRICK MARC H · October 1, 2026 · Option Exercise6.4K
- Ronald Asbury Andrews · October 1, 2026 · Option Exercise921
- Clowes Howard · October 1, 2026 · Option Exercise921
- van Es-Johansson An · October 1, 2026 · Option Exercise921
- Richard J. Hawkins · October 1, 2026 · Option Exercise921
- Sims Andrew John Hugh MacIntyre · October 1, 2026 · Option Exercise287
- Sims Andrew John Hugh MacIntyre · October 1, 2026 · Option Exercise1.2K
- Sims Andrew John Hugh MacIntyre · October 1, 2026 · Option Exercise1.5K
- HEDRICK MARC H · October 1, 2026 · Option Exercise2.0K
- HEDRICK MARC H · October 1, 2026 · Option Exercise8.1K
- Guse Kyle · October 1, 2026 · Option Exercise921
Institutional Ownership
March 31, 2026
- Total shares held
- 2.6K
- Total value held
- $430
- Institutional holders
- 1
Top holders this quarter
- Unknown2.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cerenome projects $1.55M in Q3 CNSide billings
Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.
Cerenome projects $1.55M in Q3 CNSide billings. Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.